investor fraud

Immutep faces class action lawsuit alleging investor deception over TACTI-004 trial failure. Stock plunged 83% after March discontinuation announcement, despite positive January guidance. Lead plaintiff deadline: July 6, 2026.

Law firm Kahn Swick & Foti initiates investigation into Sportradar ($SRAD) alleging fraud and unlawful business practices by company officers and directors.

Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.

Trip.com shareholders sue over undisclosed regulatory risks tied to AI pricing tool. Stock crashed 17% after Chinese anti-monopoly investigation; co-founders resigned.

Trip.com faces class action lawsuit over undisclosed regulatory risks after 17% stock drop following Chinese antitrust investigation into its AI pricing tool.

Aardvark Therapeutics ($AARD) plummeted 56% after pausing Phase 3 HERO trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.

Class action lawsuit filed against $SNOW for allegedly concealing negative revenue impact of product efficiency features. Investors have until April 2026 deadline.

Law firm Holzer & Holzer filed shareholder class actions against $NUAI and $GOSS for allegedly making materially false statements. Investors have until June 1, 2026 to seek lead plaintiff status.

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.

Rosen Law Firm notifies investors in $CWH securities class action alleging material misstatements on inventory management and consumer demand. Lead plaintiff deadline: May 11, 2026.

Hercules Capital ($HTGC) faces securities class action after short seller claims Google Ventures copying, valuation overstatement, and PIK loan misuse.

Corcept Therapeutics faces class action lawsuit alleging misrepresentation of relacorilant clinical trial data and FDA approval prospects. Investors from Oct 2024-Dec 2025 may seek compensation.

ImmunityBio ($IBRX) shares plunged 21% after FDA warning over false Anktiva efficacy claims, erasing $2 billion in market value and triggering securities litigation.

Apollo Global Management sued over alleged false statements regarding Jeffrey Epstein relationship. Stock plunged 15%, wiping $12B in market cap following investigative revelations.

Robbins LLP files class action against $SLNO over safety concerns regarding its Prader-Willi syndrome drug, following critical exposé and patient death disclosure.

Trip.com shares crashed 17% after Chinese regulators launched anti-monopoly probe into allegedly coercive AI pricing tool. Securities lawsuit filed.

Trip.com shares crashed 17% amid Chinese antitrust probe into AI pricing tool allegedly forcing hotel discounts. Securities lawsuit filed; company shut tool down.

Richtech Robotics faces securities class action after Microsoft denied partnership, stock crashed 20% following 30% surge on alleged false collaboration announcement.

Trip.com shares crater 17% after Chinese regulators investigate alleged anticompetitive AI pricing tool. Securities lawsuit filed; company shuts down tool.

EOSE shares plunged 39% after missing FY 2025 revenue targets by 25% and revealing manufacturing delays. Securities lawsuit alleges management concealed production issues from investors.